Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AscellaHealth Releases Q1 2025 Specialty & Rare Pipeline Digest™ Providing Essential Clinical Drug Updates

PipelineDigest_2025Q1_MAR-190-031425.3_Page_01

BERWYN, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today unveiled its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches and approvals, biosimilars and cell and gene therapies (CGTs). As the intricate specialty pharmaceutical landscape evolves with emerging therapies, this complimentary quarterly publication equips stakeholders with vital, timely updates into specialty product pipelines.

"The steady pace of FDA approvals for novel therapies and shifts in treatment approaches, especially in the specialty and orphan drug areas, highlight the demand for these timely, actionable insights to advance treatment options for complex and rare conditions,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “Developed by our talented and dedicated team of clinical researchers and analytics experts, this robust publication empowers manufacturers, payers and providers with the knowledge to strategically navigate this dynamic landscape, supporting our commitment to enhancing patient access to treatment and product affordability."

A Look Back: 2024
In 2024, the FDA approved 50 novel drugs, slightly fewer than the 55 approved in 2023, but still above the 10-year average of 47 approvals annually. Over half of these new drugs target rare or orphan diseases. Furthermore, 66% of the approvals were fast-tracked through at least one of the FDA's expedited programs designed to address serious health conditions, with 16% receiving accelerated approval, reflecting a continued drive for innovation in patient care and the potential to enhance public health.

Projected Trends: 2025-2026
Projections for 2025–2026 indicate that trends will remain similar to those of 2024–2025, despite the introduction of several high-cost treatments for rare diseases. Specialty drugs are expected to continue growing as a significant portion of overall drug spending, with these medications accounting for more than half of total drug expenditures in 2025-2026 and beyond.

Growth in Specialty and Orphan Drug Approvals:
The FDA’s focus on specialty medications and orphan drugs continues to expand, with 71% of recent submissions being for specialty medications and 34% for orphan drugs. This trend reflects a growing commitment to addressing complex and rare conditions through innovative treatments.

Read more findings in the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f14bad2-92c2-429a-b11e-d33acd247fe7

This press release was published by a CLEAR® Verified individual.


Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.